AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DIMERIX LTD

0.435

+0.000

Volume:989.72K

Turnover:430.17K

Market Cap:242.89M

PE:-9.84

High:0.445

Open:0.440

Low:0.425

Close:0.435

Loading ...

Overview Company News Filings

Dimerix inks agreement for development, commercialisation of kidney disease drug in Japan

The Market Herald

Guess which ASX healthcare stock is up 31% on big news

ASX Market Open: Oz bourse to wade through Trump tariff turbulence, iron ore slump to open up | Jan 7, 2024

The Market Herald

Dimerix - Dimerix and Fuso Enter Into Exclusive Development and License Agreement to Commercialise Dmx-200 in Japan

THOMSON REUTERS

Dimerix Completes Part Two of Recruitment for Phase 3 Kidney Disease Trial

MT Newswires Live

ASX Market Open: Countdown to New Year brings red dip to Aussie market | Dec 30, 2024

The Market Herald

We're Interested To See How Dimerix (ASX:DXB) Uses Its Cash Hoard To Grow

Simply Wall St.

The sectors and stocks set for a big 2025

There's more to Australian biotech than just CSL: the opportunities to watch

Dimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%

MT Newswires Live

Companies Like Dimerix (ASX:DXB) Can Afford To Invest In Growth

Simply Wall St.

Dimerix to Boost Patient Recruitment in the UK After Rare Kidney Disease Registry Collaboration, says Euroz Hartleys

MT Newswires Live

Dimerix Partners with UK's Rare Kidney Disease Registry for Recruitment for ACTION3 Phase Three Clinical Trial

MT Newswires Live

Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.91 From AU$0.86; Keeps at Speculative Buy

MT Newswires Live

Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.91 From AU$0.86; Keeps at Speculative Buy

MT Newswires Live

Dimerix to Receive 'Commercial Incentives' if Expanded Kidney Disease Trial on Pediatric Patients Succeeds, Euroz Hartleys Says; Shares Fall 4%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.435,"timestamp":1741233060883,"preClose":0.435,"halted":0,"volume":989721,"delay":0,"changeRate":0,"change":0,"floatShares":437568654,"shares":558361086,"eps":-0.044195,"lyrEps":-0.0377,"pbRate":33.88,"amount":430170,"amplitude":0.045977,"volumeRatio":0.917603,"dividePrice":0,"prevYearClose":0.34,"fiveDayClose":0.455,"twentyDayClose":0.465},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":437568654,"roa":"-79.26%","roe":"-524.68%","lyrEps":-0.0377,"volumeRatio":0.917603,"shares":558361086,"dividePrice":0,"high":0.445,"amplitude":0.045977,"preClose":0.435,"low":0.425,"week52Low":0.26,"pbRate":"33.88","psRate":"329.17","week52High":0.665,"institutionHeld":0,"latestPrice":0.435,"committee":0.605362,"eps":-0.044195,"divideRate":0,"volume":989721,"delay":0,"ttmEps":-0.044195,"open":0.44,"prevYearClose":0.34,"prevWeekClose":0.435,"prevMonthClose":0.435,"prevQuarterClose":0.34,"fiveDayClose":0.455,"twentyDayClose":0.465,"sixtyDayClose":0.355},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501942072","title":"Dimerix inks agreement for development, commercialisation of kidney disease drug in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2501942072","media":"The Market Herald","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501942072?lang=en_us&edition=fundamental","pubTime":"2025-01-07 07:54","pubTimestamp":1736207640,"startTime":"0","endTime":"0","summary":"Biopharmaceutical company Dimerix Ltd  has partnered with Japanese company FUSO to progress the development and commercialisation of its drug DMX-200 for the treatment of focal segmental glomerulosclerosis  kidney disease.According to the exclusive development and license agreement, FUSO Pharmaceutical Industries Ltd will acquire exclusive rights to develop, register, and commercialise DMX-200 in Japan, taking on all clinical trial costs within the country.The candidate is currently in global Phase 3 clinical development, with a blinded interim analysis expected in August 2025.Dimerix – which retains all commercialisation rights for DMX-200 in all territories otherthan those covered by its agreements with FUSO, Advanz Pharma, and Taiba – will receive up to 10.5 billion  in upfront, development, and sales milestone payments, as well as through royalties.CEO and managing director Dr Nina Webster said Dimerix was pleased to enter this partnership for the development of the candidate in Ja","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-inks-agreement-for-development-commercialisation-of-kidney-disease-drug-in-japan-2025-01-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["DXB.AU","FSGS","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2501329422","title":"Guess which ASX healthcare stock is up 31% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2501329422","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501329422?lang=en_us&edition=fundamental","pubTime":"2025-01-07 07:45","pubTimestamp":1736207112,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  shares are catching the eye of investors on Tuesday. In morning trade, the ASX healthcare stock is up 31% to 46.5 cents. Why is this ASX healthcare stock rocketing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/07/guess-which-asx-healthcare-stock-is-up-31-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["DXB.AU","FSGS","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2501209294","title":"ASX Market Open: Oz bourse to wade through Trump tariff turbulence, iron ore slump to open up | Jan 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2501209294","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501209294?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:48","pubTimestamp":1736200080,"startTime":"0","endTime":"0","summary":"The ASX 200 index is expected to open as much as 0.36% higher today, adding 29.9 points in futures, which would mark the local bourse’s fourth green day in a row – a trend it just barely held on to yesterday at close.U.S. markets were certainly mixed overnight as President-elect Donald Trump – who was just hours ago certified as 2024’s election winner – came out swinging against a report from the Washington Post that suggested a narrower tariff plan had been tabled in his war room and was still being heavily considered by his team.In stock moves specifically, technology heavyweights locked in enough gains to push the Nasdaq composite 1.2% higher; the S&P 500 added 0.6%.GenusPlus Group  has completed its Geographe Tree Services acquisition after the vegetation management pickup originally got rolling in November.HotCopper forum users have also earmarked West Cobar Metals  as one to watch closely today after the rare earths and battery minerals explorer landed “outstanding” first-pass fl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-oz-bourse-to-wade-through-trump-tariff-turbulence-iron-ore-slump-to-open-up-jan-7-2024-2025-01-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["WC1.AU","BK7508","BHP.AU","RIO.AU","BK7055","BK7067","DXB.AU","BK7511","BK7507","FMG.AU","BK7095","BK7501","GNP.AU","BK7129"],"gpt_icon":0},{"id":"2501826083","title":"Dimerix - Dimerix and Fuso Enter Into Exclusive Development and License Agreement to Commercialise Dmx-200 in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2501826083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501826083?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:23","pubTimestamp":1736198607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O21KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2495685705","title":"Dimerix Completes Part Two of Recruitment for Phase 3 Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2495685705","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495685705?lang=en_us&edition=fundamental","pubTime":"2024-12-31 08:45","pubTimestamp":1735605900,"startTime":"0","endTime":"0","summary":"Dimerix  completed the second part of recruitment for its phase 3 kidney disease trial investigating the use of the DMX-200 in patients with focal segmental glomerulosclerosis, a form of kidney disease, according to a Tuesday filing with the Australian bourse.The study, named DMX-200 Action3, recruited its 144th patient, effectively completing 50% of the total recruitment for the trial, the filing said. Patients were randomized and dosed with either the medication or placebo over 35 weeks.The company expects to complete the recruitment of all 286 adult patients in the third quarter of 2025, the filing said.The company's shares slipped almost 1% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2495515955","title":"ASX Market Open: Countdown to New Year brings red dip to Aussie market | Dec 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2495515955","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495515955?lang=en_us&edition=fundamental","pubTime":"2024-12-30 05:43","pubTimestamp":1735508580,"startTime":"0","endTime":"0","summary":"The second last day of the year on the Australian stock exchange looks red, with the shortened holiday trading week’s futures down just over 29 points – a 0.35% drop – as the Aussie bourse grinds to a sluggish end to the 2025 season.The dip at open comes after Wall Street’s holiday struggles; the U.S. markets were dragged down by the Magnificent Seven, most of which suffered sharp declines.Microsoft was one of the biggest losers, down 1.7%; Nvidia dropped even more, -2.1%.With the post-Christmas slowdown buying-wise getting into full swing, retail heavyweights like Amazon  and Best Buy  were also impacted – a trend that should now continue.Strike Energy  – the most watched Aussie stock on HotCopper forums through 2024 – will be a mover on Monday after sharing its Walyering East-1 results.Clinical-stage biopharmaceutical company Dimerix Limited  also shared news right before the close of the year, updating shareholders on its DMX-200 Action3 third-phase trials second run in a morning re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-countdown-to-new-year-brings-red-dip-to-aussie-market-dec-30-2024-2024-12-30/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["STX.AU","BK7501","BK7508","BK7067","DXB.AU","BK7142","CEL.AU","BK7095"],"gpt_icon":0},{"id":"2493389282","title":"We're Interested To See How Dimerix (ASX:DXB) Uses Its Cash Hoard To Grow","url":"https://stock-news.laohu8.com/highlight/detail?id=2493389282","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493389282?lang=en_us&edition=fundamental","pubTime":"2024-12-21 04:26","pubTimestamp":1734726408,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-dxb/dimerix-shares/news/were-interested-to-see-how-dimerix-asxdxb-uses-its-cash-hoar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DXB","BK7508","BK7067","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2491504636","title":"The sectors and stocks set for a big 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2491504636","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491504636?lang=en_us&edition=fundamental","pubTime":"2024-12-16 07:40","pubTimestamp":1734306015,"startTime":"0","endTime":"0","summary":"Recovery to opportunity: Microcaps to benefit from shifting economic winds. 2024 saw a shift in performance for microcap companies after two consecutive years of challenging conditions. The S&P/ASX Emerging Companies Index has returned an impressive 27.88% . However, on a 3-year CAGR basis the index is still recovering, with a -2.40% p.a. return compared to +9.25% p.a. from the ASX 50.Healthcare: Dermatology business Botanix Pharmaceuticals  secured FDA approval for their novel drug to treat hyperhidrosis this year. The commercial launch earmarked for early 2025 will see first sales and prove out the product’s attractive economics. Dimerix  is conducting phase 3 trials for a rare kidney disease, with results expected towards the end of the calendar year. With portfolio holdings radiology business Capitol Health  and dentist franchise Pacific Smi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-sectors-and-stocks-set-for-a-big-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-sectors-and-stocks-set-for-a-big-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["MLX.AU","XJO.AU","AMI.AU","SXE.AU","BK7096","DXB.AU","XRF.AU","SND.AU","EGH.AU","GDG.AU","BK7502","XAO.AU","BK7508","BK7067","CAJ.AU","BK7507","RUL.AU","XKO.AU","BK7164","AQZ.AU","BK7133","PSQ.AU","BK7030","BK7016","BK7088","BK7124","BK7095","BK7055","BK7113","BOT.AU","BK7089","BK7501","BK7506"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=fundamental","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["CSL","BK7501","NEU.AU","CVB.AU","SNT.AU","BK7511","BK4086","LU0728928796.USD","BK7096","OPT.AU","CSL.AU","LU1169589451.USD","BK7508","XAO.AU","BK7502","XJO.AU","DXB.AU","TLX.AU","BOT.AU","LU1169590202.USD","IMM.AU","BK7007","BK7067","SGXZ23171101.USD","SG9999004303.SGD","XKO.AU"],"gpt_icon":0},{"id":"2485896204","title":"Dimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485896204","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485896204?lang=en_us&edition=fundamental","pubTime":"2024-11-21 11:14","pubTimestamp":1732158895,"startTime":"0","endTime":"0","summary":"Biopharmaceutical company Dimerix  confirmed that the fifth Independent Data Monitoring Committee  review of the Action3 phase 3 trial data identified no safety concerns and recommended the trial's continuation, according to a Wednesday filing with the Australian bourse.The study is evaluating the efficacy and safety of the company's product candidate DMX200 in patients with focal segmental glomerulosclerosis kidney disease, the filing said.The next IDMC meeting is scheduled for the second quarter of 2025, according to the filing.Dimerix shares fell nearly 3% in afternoon trade Thursday.Price : $0.33, Change: $-0.01, Percent Change: -2.99%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","LU1043141123.HKD","LU0426412945.USD","DXB.AU","BK7501","LU2238339852.HKD","AUD","LU0345774631.USD","BK7508","BK7067","BK4125","LU0426417589.USD"],"gpt_icon":0},{"id":"2485042103","title":"Companies Like Dimerix (ASX:DXB) Can Afford To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2485042103","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485042103?lang=en_us&edition=fundamental","pubTime":"2024-11-21 07:35","pubTimestamp":1732145735,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. By way of example, Dimerix  has seen its share price rise 139% over the last year, delighting many shareholders. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.Given its strong share price performance, we think it's worthwhile for Dimerix shareholders to consider whether its cash burn is concerning. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.Since it has a market capitalisation of AU$187m, Dimerix's AU$7.0m in cash burn equates to about 3.8% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/companies-dimerix-asx-dxb-afford-233535920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7067","BK7508","DXBO.AU","DXB","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2468090288","title":"Dimerix to Boost Patient Recruitment in the UK After Rare Kidney Disease Registry Collaboration, says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2468090288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468090288?lang=en_us&edition=fundamental","pubTime":"2024-09-17 10:29","pubTimestamp":1726540193,"startTime":"0","endTime":"0","summary":"Biopharmaceutical business Dimerix  should see boosted recruitment rates in the UK for its trial of focal segmental glomerulosclerosis  after it entered a collaboration with the largest rare kidney disease registry in the world, the UK's National Registry of Rare Kidney Diseases , according to a research note from Euroz Hartleys.RaDaR has more than 34,500 rare kidney disease patients recruited from 109 hospitals in the UK, with plans to identify patients suitable for Phase 3 of Dimerix's trial, the note stated.Euroz Hartleys maintained its speculative buy rating and AU$0.91 price target on Dimerix.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7501","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2467168865","title":"Dimerix Partners with UK's Rare Kidney Disease Registry for Recruitment for ACTION3 Phase Three Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2467168865","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467168865?lang=en_us&edition=fundamental","pubTime":"2024-09-16 11:23","pubTimestamp":1726456998,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","BK7067","AUD","BK4125","BK7501"],"gpt_icon":0},{"id":"2467712729","title":"Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.91 From AU$0.86; Keeps at Speculative Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2467712729","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467712729?lang=en_us&edition=fundamental","pubTime":"2024-09-13 16:12","pubTimestamp":1726215172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4125","BK7501","BK7508","AUD","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2467371276","title":"Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.91 From AU$0.86; Keeps at Speculative Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2467371276","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467371276?lang=en_us&edition=fundamental","pubTime":"2024-09-13 16:12","pubTimestamp":1726215172,"startTime":"0","endTime":"0","summary":"Price (AUD): $0.42, Change: $-0.020, Percent Change: -4.60%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU"],"gpt_icon":0},{"id":"2467912567","title":"Dimerix to Receive 'Commercial Incentives' if Expanded Kidney Disease Trial on Pediatric Patients Succeeds, Euroz Hartleys Says; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467912567","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467912567?lang=en_us&edition=fundamental","pubTime":"2024-09-13 13:23","pubTimestamp":1726205037,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["AUD","BK4125","DXB.AU","BK7501","BK7067","DXB","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":2,"totalSize":43}]}}